Helsinn Healthcare SA

2 marketed · 5 in Phase 3

Quick facts

Marketed products

Akynzeo solution · Oncology
Akynzeo is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) that prevents chemotherapy-induced nausea and vomiting by blocking two key pathways in the chemoreceptor trigger zone and gastrointestinal tract.
fosnetupitant/ palonosetron · Oncology
Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract.

Phase 3 pipeline

I.V. palonosetron · Oncology
Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Oral palonosetron · Oncology
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting.
Placebo to Ondansetron · Oncology, Gastroenterology, Anesthesia
Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Placebo to Palonosetron · Oncology
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy.
Pro-netupitant/Palonosetron · Oncology
Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist.

Phase 2 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Helsinn Healthcare SA

What are Helsinn Healthcare SA's marketed drugs?

Top marketed products include Akynzeo solution, fosnetupitant/ palonosetron.

What is Helsinn Healthcare SA's pipeline?

Helsinn Healthcare SA has 5 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include I.V. palonosetron, Oral palonosetron, Placebo to Ondansetron, Placebo to Palonosetron.

Akynzeo solution · Oncology
fosnetupitant/ palonosetron · Oncology
Sector hub: All tracked pharma companies